OncoMatch/Clinical Trials/NCT05746897
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Is NCT05746897 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including NM1F and Pembrolizumab for ovarian cancer.
Treatment: NM1F · Pembrolizumab — A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination with Pembrolizumab in Subjects with Locally Advanced/Metastatic Solid Tumors
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Melanoma
Triple-Negative Breast Cancer
Breast Carcinoma
Colorectal Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard therapy
who have progressed despite all standard therapy or are intolerant of all standard therapy, or for whom no effective standard therapy exists
Cannot have received: anti-PVRIG therapy (COM701, other anti-PVRIG mAb)
Any therapy directed against PVRIG (COM701 or other anti-PVRIG mAb) or other CD226 axis receptor (TIGIT or CD96) at any time
Cannot have received: CD226 axis receptor therapy (TIGIT, CD96)
Any therapy directed against PVRIG (COM701 or other anti-PVRIG mAb) or other CD226 axis receptor (TIGIT or CD96) at any time
Cannot have received: chemotherapy
Chemotherapy, target therapy, immunotherapy, or other anticancer therapy within 28 days or 5 half-lives, whichever is shorter, prior to the first dose of study treatment
Cannot have received: targeted therapy
Chemotherapy, target therapy, immunotherapy, or other anticancer therapy within 28 days or 5 half-lives, whichever is shorter, prior to the first dose of study treatment
Cannot have received: immunotherapy
Chemotherapy, target therapy, immunotherapy, or other anticancer therapy within 28 days or 5 half-lives, whichever is shorter, prior to the first dose of study treatment
Cannot have received: radiation therapy
Exception: single fraction of radiotherapy for palliation permitted
Prior radiotherapy ≤ 4 weeks prior to the first dose of study treatment, with the exception of a single fraction of radiotherapy for the purposes of palliation, which is permitted
Cannot have received: investigational therapy
Investigational therapy: if the subject has participated in a clinical study and has received an investigational product within 4 weeks prior to the first dose of study treatment
Lab requirements
Blood counts
sufficient baseline organ function and laboratory data
Kidney function
sufficient baseline organ function and laboratory data
Liver function
sufficient baseline organ function and laboratory data
Subjects have sufficient baseline organ function and laboratory data
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NEXT Oncology, Dallas · Dallas, Texas
- Next Oncology, Virginia Cancer Specialists · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify